GLP-1 receptor agonists

Duopoly entrenched, but the moat is moving from molecule to manufacturing

Novo Nordisk and Eli Lilly together hold roughly 90% of the GLP-1 prescription market, but the balance inside the duopoly has flipped: Lillys tirzepatide franchise (Mounjaro, Zepbound) overtook Novos semaglutide franchise (Ozempic, Wegovy, Rybelsus, oral Wegovy) in 2025–26, reaching about 60% of the US obesity/diabetes drug market and above 53% outside the US in Q1 2026. Lillys combined Mounjaro+Zepbound revenue was $12.8B in Q1 2026 alone (Mounjaro up ~125% YoY); Novo is restructuring under new CEO Mike Doustdar. The moat is also shifting at the category level. Semaglutides composition-of-matter patent begins expiring around 2026–27 in several markets (US later; formulation patents extend to ~2031), and compounding-pharmacy and generic pressure erodes the molecular monopoly earlier than the headline date. What sustains the duopoly is manufacturing scale (sterile peptide fill-finish, cagrilintide synthesis for CagriSema, oral-formulation bioavailability for orforglipron), clinical-evidence depth across cardiovascular and obesity-adjacent indications, and payer-access infrastructure. The competitive question for 2027–2030 is whether the manufacturing-and-evidence moat outlasts the molecular one.

State of the art (2026)

By mid-2026 the GLP-1 category is a Novo Nordisk-Lilly duopoly extending in three directions at once. Oral delivery has arrived: oral Wegovy cleared the FDA in December 2025 and Lilly's orforglipron (Foundayo), the first non-peptide oral GLP-1, was approved for weight management on 1 April 2026, with a type 2 diabetes filing pending. Efficacy keeps climbing — Lilly's triple agonist retatrutide read out TRIUMPH-1 in May 2026 at roughly 28% weight loss, while Novo's CagriSema (~22-23%) awaits an FDA decision expected late 2026 after losing a head-to-head to Zepbound. Indication expansion (cardiovascular, sleep apnoea, MASH, Alzheimer's via the evoke trials) and the looming semaglutide patent cliff now define the competitive frontier.

Oral and non-peptide formulations remove the injection ceiling

The original constraint on GLP-1 adoption was injection-aversion — estimated at ~40% of addressable patients. That constraint has effectively been removed. Novo Nordisks oral Wegovy (high-dose oral semaglutide) was FDA-approved on 22 December 2025 and launched January 2026 (OASIS-4: ~16.6% weight loss). Eli Lillys orforglipron/Foundayo — the first non-peptide small-molecule oral GLP-1, no refrigeration, no food restrictions — was FDA-approved for weight management on 1 April 2026, with a type 2 diabetes filing planned. In Lillys ACHIEVE-3 trial orforglipron 36mg delivered A1C reduction of −2.2% vs oral semaglutide 14mgs −1.4%, and weight reduction of −19.7lb vs −11.0lb. Oral expansion does three things: (a) widens the addressable patient pool, (b) compresses Novos structural advantage in injectable franchises, and (c) lowers the cold-chain barrier for global access. The remaining ceiling is supply and price, not delivery format.

Next-generation efficacy expands the market rather than fragmenting it

The pipeline is converging on three frontiers: combination agonists (CagriSema = semaglutide + cagrilintide amylin analogue; Novo Phase 3 REDEFINE delivered ~22-23% mean weight loss, FDA decision expected late 2026, though REDEFINE 4 failed non-inferiority vs Zepbound), triple-hormone agonists (Lillys retatrutide = GLP-1 + GIP + glucagon; TRIUMPH-1 read out May 2026 at ~28% weight loss at 80 weeks, FDA decision likely 2027–28), and adjacent indications (Zepbound approved for obstructive sleep apnoea; cardiovascular outcome trials drive formulary expansion; Alzheimers, MASH, and addiction trials in various phases). Higher-efficacy successors do not fragment the category — they extend it vertically. A patient on Wegovy or Zepbound at −15% is a candidate to step up to CagriSema or retatrutide for −22-28%, then down to oral maintenance on orforglipron. The structural read: bigger TAM rather than displacement.